{
    "organizations": [],
    "uuid": "3842060cb64d3db2dcb2f6dc76f3ecfa272c453d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-novo-nordisk-says-does-not-intend/brief-novo-nordisk-says-does-not-intend-to-make-a-revised-proposal-for-ablynx-idUSC7N1JW009",
    "ord_in_thread": 0,
    "title": "BRIEF-Novo Nordisk Says Does Not Intend To Make A Revised Proposal For Ablynx",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 29 (Reuters) - NOVO NORDISK A/S:\n* NOVO NORDISK SAYS DOES NOT INTEND TO MAKE A REVISED PROPOSAL FOR ABLYNX\n* NOVO NORDISK SAYS LOOKS FORWARD TO CONTINUE ITS PRODUCTIVE RESEARCH COLLABORATION WITH ABLYNX\n* FRENCH DRUGMAKER SANOFI SAID ON MONDAY IT HAS AGREED TO BUY THE BELGIAN BIOTECH COMPANY FOR 3.9 BILLION EUROS ($4.8 BILLION) FURTHER COMPANY COVERAGE: (Reporting by Stine Jacobsen)\n ",
    "published": "2018-01-29T18:11:00.000+02:00",
    "crawled": "2018-01-30T19:03:37.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "novo",
        "nordisk",
        "novo",
        "nordisk",
        "say",
        "intend",
        "make",
        "revised",
        "proposal",
        "ablynx",
        "novo",
        "nordisk",
        "say",
        "look",
        "forward",
        "continue",
        "productive",
        "research",
        "collaboration",
        "ablynx",
        "french",
        "drugmaker",
        "sanofi",
        "said",
        "monday",
        "agreed",
        "buy",
        "belgian",
        "biotech",
        "company",
        "billion",
        "euro",
        "billion",
        "company",
        "coverage",
        "reporting",
        "stine",
        "jacobsen"
    ]
}